Pancreatic Adenocarcinoma

An estimated 33,370 people will die of pancreatic cancer in the United States in 2007, making it the fourth most common cause of cancer-related death among men in the United States. Although incidence is roughly equal among men and women, African Americans appear to have a higher incidence of pancreatic cancer than white Americans. The NCCN Pancreatic Adenocarcinoma Guidelines discuss risk factors, diagnosis and staging, and treatment through palliative care or surveillance for patients with tumors of the exocrine pancreas. Overall, in view of the poor outcome of patients with all stages of pancreatic cancer, the NCCN panel recommends that investigational options be considered in all phases of disease management. Specific palliative measures are recommended for patients with advanced pancreatic adenocarcinoma characterized by biliary or gastric obstruction, severe abdominal pain, or other tumor-associated manifestations of the disease.

For the most recent version of the guidelines, please visit NCCN.org

If the inline PDF is not rendering correctly, you can download the PDF file here.

Known worldwide for its expertise in the diagnosis and treatment of pediatric cancers, St. Jude Children's Research Hospital (www.stjude.org) is dedicated to saving children's lives by finding the causes of catastrophic illnesses, improving treatment, and developing cures. St. Jude is internationally known for its treatment of all pediatric cancers, but is particularly esteemed for its treatment of brain tumors, leukemia, lymphoma, neuroblastoma, osteosarcoma, and retinoblastoma. St. Jude oncologists are also experts in gene therapy and pediatric stem cell transplantation. Founded by late entertainer Danny Thomas and based in Memphis, Tennessee, St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit the web site.William E. Evans, PharmD (second photo), assumed the position of St. Jude Director and CEO in 2004. Previously the hospital's scientific director, Dr. Evans has published more than 250 research articles and has received 3 MERIT Awards from the National Institutes of Health for his research.Michael Kastan, MD, PhD (third photo), is the director of the St. Jude Cancer Center. Dr. Kastan's laboratory is making major strides in elucidating how DNA damage affects cancer development.St. Jude works in partnership with University of Tennessee and the University of Tennessee Cancer Institute.
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 229 188 6
PDF Downloads 22 22 20
EPUB Downloads 0 0 0